MASS
908 Devices Inc.
MASS lost money over the past year, so it has no meaningful PE right now.
MASS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Healthy | |
| Unavailable |
MASS's revenue and cash flow are currently healthy, but its profitability is weak. There isn't enough data to rate its balance sheet.
MASS PE Valuation
MASS has no meaningful PE right now: it lost money over the past year.
MASS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect MASS's revenue to grow and its profitability to improve, with its earnings holding steady. However, they disagree widely on these estimates.
MASS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.66 | -$0.53 |
| Q2 2026 | -$0.96 | -$0.40 |
| Q1 2026 | -$1.01 | -$0.45 |
| Q4 2025 | $0.54 | +$2.66 |
| Q3 2025 | -$0.13 | +$1.64 |
| Q2 2025 | -$0.56 | +$0.59 |
| Q1 2025 | -$0.56 | +$0.51 |
| Q4 2024 | -$2.12 | -$0.99 |
MASS is still losing money, but far less than before: $0.66 per share over the past year, against $2.12 at its worst in late 2024.
MASS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19M | +35% |
| Q2 2026 | $16.1M | +23% |
| Q1 2026 | $13.4M | +14% |
| Q4 2025 | $17.4M | -7.7% |
| Q3 2025 | $14M | -17% |
| Q2 2025 | $13M | -7.2% |
| Q1 2025 | $11.8M | +18% |
| Q4 2024 | $18.8M | +31% |
MASS's revenue is growing: $19M last quarter, up 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -29% | +88 points |
| Q2 2026 | -80% | +37 points |
| Q1 2026 | -96% | -2.7 points |
| Q4 2025 | 18% | +125 points |
| Q3 2025 | -117% | +64 points |
| Q2 2025 | -116% | -20 points |
| Q1 2025 | -94% | +33 points |
| Q4 2024 | -108% | -40 points |
MASS's operating margin was −29% last quarter, up 88 points from the same quarter a year ago.
MASS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.9M | +$2M |
| Q2 2026 | $3M | +$8.9M |
| Q1 2026 | $1.2M | +$16.3M |
| Q4 2025 | $1.3M | +$3.8M |
| Q3 2025 | -$4.9M | +$879K |
| Q2 2025 | -$5.9M | +$6.5M |
| Q1 2025 | -$15.2M | -$4.9M |
| Q4 2024 | -$2.4M | -$170K |
MASS's free cash flow has turned positive after six years mostly in the red: $3M over the past year.
MASS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8.9% | +3.3M shares |
| 1 year | +14% | +5M shares |
| 3 years | +27% | +8.7M shares |
| 5 years | +48% | +13.4M shares |
| Available history | +492% | +34.1M shares |
MASS has 41M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
MASS Net Leverage
MASS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MASS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.5 | Neutral |
| Stochastic | 46.7 | Neutral |
MASS's weekly RSI is 51 (neutral) and its Stochastic is 47 (neutral).
MASS PE vs Healthcare Sector
MASS has no meaningful PE right now: it lost money over the past year.
MASS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.3 | 14% below |
| 20 week MA | $10.0 | 2.2% below |
| 50 week MA | $8.06 | 21% above |
| 100 week MA | $6.71 | 46% above |
| 200 week MA | $6.59 | 49% above |
MASS has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 49% above its 200-week average.
MASS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $49.0 | $67.9 | +39% |
| 2021 | $67.9 | $26.6 | -61% |
| 2022 | $26.6 | $7.31 | -73% |
| 2023 | $7.31 | $11.2 | +53% |
| 2024 | $11.2 | $2.26 | -80% |
| 2025 | $2.26 | $5.41 | +139% |
| 2026 YTD | $5.41 | $9.79 | +81% |
MASS's yearly returns have swung widely, from +139% in 2025 to −80% in 2024. It's up 81% so far in 2026.